Stock 1349 SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Equities

1349

CNE1000000W4

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:16 2024-05-02 EDT 		5-day change 1st Jan Change
2.16 HKD 0.00% Intraday chart for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. +2.37% -15.29%
04-29 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-22 Shanghai Fudan-Zhangjiang Buys Structured Deposits Worth 200 Million Yuan MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023, Payable on August 26, 2024
Fudan-Zhangjiang Bio's 2023 Profit Falls
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Fudan-Zhangjiang Bio-Pharmaceutical to Subscribe for Deposit Products Worth 357 Million Yuan
Fudan-Zhangjiang Invests 357 Million Yuan in Ping An Bank Structured Deposit Products
Fudan-Zhangjiang Unit's Clinical Trial Application for Glioma Visualization Agent Accepted in China
Chinese Regulator Accepts Fudan-Zhangjiang Bio-Pharmaceutical's Application for Bladder Cancer Visualization Drug Trial
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application
Chinese Regulator NMPA Grants Acceptance Notice for Shanghai Fudan-Zhangjiang's Investigational Drug
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug
Fudan-Zhangjiang Bio-Pharmaceutical's Cancer Drug Passes Chinese Regulator’s Consistency Evaluation
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Notification of Approval for Supplementary Drug Application
Fudan-Zhangjiang's Profit Drops 70.5% in Q3
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC
Fudan-Zhangjiang Bio Swings to Profit in H1
Fudan-Zhangjiang Bio Enrolls First Patient in FZ-AD004 Clinical Trial
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Announces First Patient Enrolled in Phase I Clinical Trial of FZ-AD004 Antibody Drug Conjugate for the Treatment of Advanced Solid Tumors
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1349 Stock
  4. News Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
  5. Other languages